Anke M. Hövels

Economics, Econometrics and Finance · Social Sciences

22h-index2.7kcitations86works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(39), Pharmaceutical Economics and Policy(23), Economic and Financial Impacts of Cancer(11), Pharmaceutical Practices and Patient Outcomes(6), Prostate Cancer Treatment and Research(6)

Publications86 total

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
European Journal of Cancer·2022· 48 citedOpen Access
An <i>FCER2</i> polymorphism is associated with increased oral leukotriene receptor antagonists and allergic rhinitis prescribing
Clinical & Experimental Allergy·2021· 5 citedOpen Access
Increasing the information provided by probabilistic sensitivity analysis: The relative density plot
Cost Effectiveness and Resource Allocation·2020· 3 citedOpen Access
Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
Value in Health·2020· 9 citedOpen Access
Benchmarking health technology assessment agencies—methodological challenges and recommendations
International Journal of Technology Assessment in Health Care·2020· 3 cited
THC volume 36 issue 4 Cover and Front matter
International Journal of Technology Assessment in Health Care·2020· 1 citedOpen Access
Cost‐utility and cost‐effectiveness analysis of a clinical medication review focused on personal goals in older persons with polypharmacy compared to usual care: Economic evaluation of the DREAMeR study
British Journal of Clinical Pharmacology·2020· 24 citedOpen Access
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings
Cytotherapy·2020· 60 citedOpen Access
A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics
The European Journal of Health Economics·2020· 1 citedOpen Access
Efficacy gap between phase II and subsequent phase III studies in oncology
British Journal of Clinical Pharmacology·2020· 15 citedOpen Access
Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection
Trends in Pharmacological Sciences·2020· 8 citedOpen Access
Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations
Value in Health·2020· 54 citedOpen Access
Affordability of oncology drugs: accuracy of budget impact estimations
Journal of Market Access & Health Policy·2019· 3 citedOpen Access
PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS
Value in Health·2019Open Access
PNS328 REAL OPTIONS ANALYSIS FOR MORE OPTIMALLY INFORMED REIMBURSEMENT DECISIONS
Value in Health·2019Open Access
EP14.07: Peripartal management of fetal LQTS with polymorphic arrhythmias: high‐dose magnesium therapy, ß‐blocker and vaginal delivery
Ultrasound in Obstetrics and Gynecology·2019Open Access
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
Applied Health Economics and Health Policy·2019· 20 citedOpen Access
Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review
PharmacoEconomics - Open·2019· 3 citedOpen Access
Balancing traditional activities and cognitive pharmaceutical services by community pharmacists: a work sampling study
International Journal of Clinical Pharmacy·2019· 13 citedOpen Access
What does it cost to redispense unused medications in the pharmacy? A micro-costing study
BMC Health Services Research·2019· 22 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

G. W. J. Frederix(13), Johan L. Severens(10), Hubert G. M. Leufkens(10), Jan H.M. Schellens(9), Rick A. Vreman(8), Renske M.T. ten Ham(6), Roel A. M. Heesakkers(5), Jelle O. Barentsz(5), Joost W. Geenen(5), Marcel L. Bouvy(5), Aukje K. Mantel‐Teeuwisse(4), Wim Goettsch(4), J. G. Coen van Hasselt(4), Jan A. M. Raaijmakers(4), Olaf H. Klungel(4), Eddy Adang(3), Gerrit J. Jager(3), Jarno Hoekman(3), Olaf H. Klungel(3), Maiwenn Al(3)